We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA.
Dattola, A., Cannizzaro, M.v., Mazzeo, M., Bianchi, L. (2017). Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. DERMATOLOGY AND THERAPY, 7(4), 485-492 [10.1007/s13555-017-0208-z].
Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
Bianchi L.
2017-01-01
Abstract
We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Correction to Certolizumab.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
356.76 kB
Formato
Adobe PDF
|
356.76 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
